BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 32944402)

  • 1. Single-cell RNA-seq reveals the immune escape and drug resistance mechanisms of mantle cell lymphoma.
    Wang L; Mo S; Li X; He Y; Yang J
    Cancer Biol Med; 2020 Aug; 17(3):726-739. PubMed ID: 32944402
    [No Abstract]   [Full Text] [Related]  

  • 2. Time-Resolved scRNA-Seq Tracks the Adaptation of a Sensitive MCL Cell Line to Ibrutinib Treatment.
    Fuhr V; Vafadarnejad E; Dietrich O; Arampatzi P; Riedel A; Saliba AE; Rosenwald A; Rauert-Wunderlich H
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma.
    Zhang S; Jiang VC; Han G; Hao D; Lian J; Liu Y; Zhang R; McIntosh J; Wang R; Dang M; Dai E; Wang Y; Santos D; Badillo M; Leeming A; Chen Z; Hartig K; Bigcal J; Zhou J; Kanagal-Shamanna R; Ok CY; Lee H; Steiner RE; Zhang J; Song X; Nair R; Ahmed S; Rodriquez A; Thirumurthi S; Jain P; Wagner-Bartak N; Hill H; Nomie K; Flowers C; Futreal A; Wang L; Wang M
    Nat Commun; 2021 May; 12(1):2877. PubMed ID: 34001881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The STAT3 inhibitor WP1066 synergizes with vorinostat to induce apoptosis of mantle cell lymphoma cells.
    Lu K; Chen N; Zhou XX; Ge XL; Feng LL; Li PP; Li XY; Geng LY; Wang X
    Biochem Biophys Res Commun; 2015 Aug; 464(1):292-8. PubMed ID: 26116769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactive oxygen species mediate cancer stem-like cells and determine bortezomib sensitivity via Mcl-1 and Zeb-1 in mantle cell lymphoma.
    Luanpitpong S; Poohadsuan J; Samart P; Kiratipaiboon C; Rojanasakul Y; Issaragrisil S
    Biochim Biophys Acta Mol Basis Dis; 2018 Nov; 1864(11):3739-3753. PubMed ID: 30251692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.
    Kagiyama Y; Fujita S; Shima Y; Yamagata K; Katsumoto T; Nakagawa M; Honma D; Adachi N; Araki K; Kato A; Inaki K; Ono Y; Fukuhara S; Kobayashi Y; Tobinai K; Kitabayashi I
    Cancer Sci; 2021 Jun; 112(6):2314-2324. PubMed ID: 33792119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
    Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M
    Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential PAX5 levels promote malignant B-cell infiltration, progression and drug resistance, and predict a poor prognosis in MCL patients independent of CCND1.
    Teo AE; Chen Z; Miranda RN; McDonnell T; Medeiros LJ; McCarty N
    Leukemia; 2016 Mar; 30(3):580-93. PubMed ID: 26073757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approach.
    Chaturvedi NK; Rajule RN; Shukla A; Radhakrishnan P; Todd GL; Natarajan A; Vose JM; Joshi SS
    Mol Cancer Ther; 2013 Oct; 12(10):2006-17. PubMed ID: 23963361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single nucleotide variants in immune-response genes and the tumor microenvironment composition predict progression of mantle cell lymphoma.
    Assis-Mendonça GR; Fattori A; Rocha RM; Lourenço GJ; Delamain MT; Nonogaki S; de Lima VCC; Colleoni GWB; de Souza CA; Soares FA; Lima CSP; Vassallo J
    BMC Cancer; 2021 Mar; 21(1):209. PubMed ID: 33648463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BMP7 expression correlates with secondary drug resistance in mantle cell lymphoma.
    Camara-Clayette V; Koscielny S; Roux S; Lamy T; Bosq J; Bernard M; Fest T; Lazar V; Lenoir G; Ribrag V
    PLoS One; 2013; 8(9):e73993. PubMed ID: 24069261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
    Pham LV; Huang S; Zhang H; Zhang J; Bell T; Zhou S; Pogue E; Ding Z; Lam L; Westin J; Davis RE; Young KH; Medeiros LJ; Ford RJ; Nomie K; Zhang L; Wang M
    Clin Cancer Res; 2018 Aug; 24(16):3967-3980. PubMed ID: 29666304
    [No Abstract]   [Full Text] [Related]  

  • 13. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
    Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
    Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
    Kim A; Seong KM; Kang HJ; Park S; Lee SS
    Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A lowered 26S proteasome activity correlates with mantle lymphoma cell lines resistance to genotoxic stress.
    Ben Younes K; Body S; Costé É; Viailly PJ; Miloudi H; Coudre C; Jardin F; Ben Aissa-Fennira F; Sola B
    BMC Cancer; 2017 Aug; 17(1):538. PubMed ID: 28797244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment and Characteristics of a Novel Mantle Cell Lymphoma-derived Cell Line and a Bendamustine-resistant Subline.
    Takimoto-Shimomura T; Nagoshi H; Maegawa S; Fujibayashi Y; Tsukamoto T; Matsumura-Kimoto Y; Mizuno Y; Chinen Y; Mizutani S; Shimura Y; Horiike S; Taniwaki M; Kobayashi T; Kuroda J
    Cancer Genomics Proteomics; 2018; 15(3):213-223. PubMed ID: 29695404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy.
    Chen Z; Teo AE; McCarty N
    Clin Cancer Res; 2016 Jan; 22(1):187-99. PubMed ID: 26350264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Signal Transducer and Activator of Transcription 5B (STAT5B) Gene Promotes Proliferation and Drug Resistance of Human Mantle Cell Lymphoma Cells by Activating the Akt Signaling Pathway.
    Zhang W; Liang X; Gong Y; Xiao C; Guo B; Yang T
    Med Sci Monit; 2019 Apr; 25():2599-2608. PubMed ID: 30964854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.
    Shirsath NP; Manohar SM; Joshi KS
    Mol Cancer; 2012 Oct; 11():77. PubMed ID: 23075291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.
    Gonzalez-Santamarta M; Quinet G; Reyes-Garau D; Sola B; Roué G; Rodriguez MS
    Adv Exp Med Biol; 2020; 1233():153-174. PubMed ID: 32274756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.